The first project aims to identify the patient subtypes – clusters of people with long COVID grouped by shared characteristics – and biological mechanisms of this chronic condition, to help understand why some people are more susceptible to developing the condition. Studying the long COVID in different countries helps to understand geographical variation.
...
A second project will look to find an existing drug that can be repurposed as an effective treatment. The drug targets will be uncovered by integrating the clinical and biological similarities common to all long COVID patients, no matter their geographical regions. A major goal of this work is to provide low-cost drug interventions globally.
Both projects are supported by grants from the
Schmidt Initiative for Long COVID (SILC), a nonprofit organization founded in 2023 by Eric and Wendy Schmidt to advance clinical care for long COVID patients globally. The organization works to raise the level of long COVID care and understanding around the world, connecting specialists and primary care providers to support patients and share knowledge virtually, in real time.
...
Researchers will now begin a global interventional clinical trial with repurposed drugs that have already been approved by regulatory agencies and are available on the market to target the key signaling pathways related to long COVID – a series of chemical reactions that control the function of cells – identified in the previous project. This would mean a treatment option could be readily available to people worldwide living with this debilitating illness.
The international clinical trial will involve 1,200 patients who have been diagnosed with long COVID and participants will be assigned a repurposed drug or a placebo for the study. The researchers will then look at the symptoms, quality-of-life measures and biomarker analysis.